What I Learned Losing a Million Dollars (And Why Taleb Approves)
There are many books about how to make money. There are far fewer about how people actually lose it. What
Feeding on the Fine Print: What The Art of Vulture Investing Taught Me About Survival
There are very few finance books that you can read without needing a double espresso or a minor existential crisis
What Is Happening in Drug Discovery?
The integration of artificial intelligence (AI) into drug discovery is reshaping pharmaceutical development, prompting regulatory bodies to adapt their frameworks
The Art of "Building" a VC Track Record: How to Be Economical With the Truth
Venture capital, like any industry where past success is difficult to verify, has a long tradition of being economical with
The “Game-Changing” Illusion: How Pharma Spins Mediocre Drugs Into Miracles
Every year, the pharma industry rolls out its latest batch of “game-changing,” “best-in-class,” and “first-in-class” therapies, showering them with press
Venture Debt: A Deal With the Devil You Know
capable of wreaking havoc if overindulged. For biotech founders staring down the barrel of cash burn and trial delays, it
The Real-World Impacts of Neglecting Extreme Value Theory (EVT) in Biotech and Pharma
Focusing on the real-world impacts of neglecting Extreme Value Theory (EVT), particularly in biotechnology and pharmaceuticals, offers a potent narrative.
Decoding Kaplan-Meier Survival Analysis: A Critical Examination of Its Use and Misuse in Cancer Trials
The biotech world thrives on optimism. Pitch decks brimming with breakthroughs and life-saving treatments are a staple of the industry’
The problem with POPT
The Problem with Probability of Phase Transition (POPT) in Biotech and Pharma
Probability of Phase Transition (POPT) is a commonly
Case Studies: Failures Due to Ignoring Fat Tails in Biotech Investments
Biotech investments are uniquely characterized by uncertainty, where extreme events—whether unexpected breakthroughs or catastrophic failures—play an outsized role.
